GlassScriptPhysician profile
Ashley A Irons
NPI 1841863487
$5,558.05
in general payments reported to CMS, 2019-2025
26 companies · $991 in 2025
The $991 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,244 · 2023: $1,927 · 2024: $1,396 · 2025: $991.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,314.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,313.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $999.94 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $956.31 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $847.56 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $600.14 | 2022-2025 | |
| Lilly USA, LLC | $484.26 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $304.48 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $242.11 | 2022-2025 | Jardiance, Stiolto Respimat, Synjardy |
| Amgen INC. | $195.40 | 2022-2023 | Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $194.10 | 2022-2024 | Xifaxan, Trulance |
| Corcept Therapeutics | $188.73 | 2024-2025 | Korlym |
| Exact Sciences Corporation | $112.51 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $88.38 | 2022 | |
| Merck Sharp & Dohme LLC | $65.86 | 2022-2023 | Verquvo, Belsomra |
| Novartis Pharmaceuticals Corporation | $61.27 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.94 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $23.80 | 2025 | Aptima, Thinprep 2000 Processor |
| Ardelyx, INC. | $21.09 | 2024 | Ibsrela |
| Phadia US INC. | $20.81 | 2022 | |
| Corium, LLC | $20.04 | 2024 | Azstarys |
| Mylan Specialty L.P. | $19.61 | 2023 | Yupelri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.86 | 2022 | |
| Esperion Therapeutics, INC. | $14.26 | 2025 | Nexletol |
| Janssen Pharmaceuticals, INC | $13.82 | 2022 | |
| Azurity Pharmaceuticals, INC. | $12.94 | 2023 | Edarbyclor |
| Sanofi-Aventis U.S. LLC | $11.97 | 2022 | |
| Phathom Pharmaceuticals, INC. | $5.86 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Irons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.